Genmab — November 2022

[E_L]

The Company continues to expect TEPEZZA full-year 2022 net sales percentage growth in the high teens

[Sukkeralf]

Not bad at all

[E_L]

market seems to like it, pre market HZNP +8%

[E_L]

https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/financial-results/2022/Q3-2022-investor-presentation.pdf Novo presentation for Mim8

[E_L]

i can see no
late breaking abstract for SITC

[E_L]

GEN1056 starts recruiting. that is fast. in Moldova... https://clinicaltrials.gov/ct2/history/NCT05586321?A=1&B=2&C=merged#StudyPageTop

[gdn55]

Vitus, hvordan går det?

[Bulder]

Hznp oppe med 11%

[Vitus]

Det går helt som ventet…..Genmab er min guldåre….

[Bulder]

Hm, US dykker kraftigt efter fed. Men både gmab og nvo (ads) holder sig oppe.

[Helge_LarsenPI-redaktør]

USA/lukning: Powell sendte aktierne i dørken efter kortvarigt plus https://www.proinvestor.com/investornyt/899194/usa-lukning-powell-sendte-aktierne-i-dorken-efter-kortvarigt-plus

[Helge_LarsenPI-redaktør]

Godmorgen

[Stroka]

God morgen

[ProinvestorNEWS]

Godmorgen

[ProinvestorNEWS]

Dagens mange regnskaber: https://www.proinvestor.com/finanskalender

[bibob]

ViewPoints: Tecvayli in strong standing as soon - to - be newcomber in heavily pre-treated multiple myeloma.

[StockBull]

Ser godt ud. Så er target på 2969 ved at være i hus

[StockBull]

Har smidt de spekulative her i 2945

[bibob]

Although it fell short of response rates shown by its Car-T cell competitors the US approval of J&J ,s Tecvayli on tuesday along with some winning attributes has set it up as a major player in the multiple myeloma treatment paradigm according to key opinion leaders in the field

[E_L]

https://ir.horizontherapeutics.com/static-files/b3e39f27-2ed6-4c37-843a-d17b24e1b8b8 Horizon Q3 2022 Presentation